Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CBLB | Q13191 | 11/20 | 0.43 |
| ▸ | CBLC | Q9ULV8 | 2/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 2/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.36 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29866714 | 0.79 | HCRTR1 (0.44) | CBLBHCRTR1HCRTR2BRD4CYP17A1 | |
| SCHEMBL24662248 | 0.77 | CBLB (0.46) | CBLBIDO1 | |
| SCHEMBL24662529 | 0.75 | CBLB (0.50) | CBLBIDO1 | |
| SCHEMBL24662647 | 0.75 | CBLB (0.49) | CBLBHCRTR1HCRTR2BRD4CYP17A1 | |
| SCHEMBL31115401 | 0.74 | CBLB (0.63) | CBLBCBLCHCRTR1HCRTR2 | |
| SCHEMBL31578412 | 0.74 | CBLB (0.63) | CBLBCBLCHCRTR1HCRTR2 | |
| SCHEMBL22528116 | 0.74 | CBLB (0.41) | CBLBCBLC | |
| SCHEMBL22527975 | 0.74 | CBLB (0.43) | CBLBCBLC | |
| SCHEMBL22527977 | 0.74 | CBLB (0.43) | CBLBCBLC | |
| SCHEMBL22528110 | 0.74 | CBLB (0.43) | CBLBCBLC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11951133-B2 | 3-substituted piperidine compounds for Cbl-b inhibition, and use thereof | NURIX THERAPEUTICS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| EP-3953346-A1 | 3-SUBSTITUTED PIPERIDINE COMPOUNDS FOR CBL-B INHIBITION, AND USE OF A CBL-B INHIBITOR IN COMBINATION WITH A CANCER VACCINE AND/OR ONCOLYTIC VIRUS | Nurix Therapeutics, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| WO-2020210508-A1 | 3-SUBSTITUTED PIPERIDINE COMPOUNDS FOR CBL-B INHIBITION, AND USE OF A CBL-B INHIBITOR IN COMBINATION WITH A CANCER VACCINE AND/OR ONCOLYTIC VIRUS | NURIX THERAPEUTICS, INC. (US) | 2020-10-15 | — | — | WO | disclosed |
| US-20200323904-A1 | 3-SUBSTITUTED PIPERIDINE COMPOUNDS FOR CBL-B INHIBITION, AND USE OF A CBL-B INHIBITOR IN COMBINATION WITH A CANCER VACCINE AND/OR ONCOLYTIC VIRUS | NURIX THERAPEUTICS, INC. | 2020-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11951133-B2 | 3-substituted piperidine compounds for Cbl-b inhibition, and use thereof | CBLB, CBL, CBLC | CBLB 1/4885CBLC 3/4885HCRTR1 3975/4885 |
| US-20200323904-A1 | 3-SUBSTITUTED PIPERIDINE COMPOUNDS FOR CBL-B INHIBITION, AND USE OF A CBL-B INHIBITOR IN COMBINATION WITH A CANCER VACCINE AND/OR ONCOLYTIC VIRUS | CBLB, CBL, CBLC | CBLB 1/4885CBLC 3/4885HCRTR1 3754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.